Aimovig (erenumab-aooe) - Amgen
Zavzpret (zavegepant nasal spray) - Pfizer
Ubrelvy (ubrogepant) - AbbVie
Vyepti (eptinezumab-jjmr) - Teva, Lundbeck
Emgality (galcanezumab-gnlm) - Eli Lilly, Daiichi Sankyo
Ajovy (fremanezumab-vfrm) - Teva
Qulipta (atogepant) - AbbVie
Nurtec ODT (rimegepant ODT) - Pfizer
Anti-calcitonin gene-related peptide treatments in women's health: Gaps and clinical evidence in menstrual-related migraine, pregnancy, lactation, and hormonal contraception: A narrative review. (PubMed, Headache) - Sep 30, 2026 - "Substantial evidence gaps exist across all reproductive health contexts examined. Prospective trials in menstrual-related migraine, pregnancy registries, lactation studies assessing infant outcomes, and research examining interactions with hormonal contraceptives are needed to optimize migraine care for women." 
Journal • Review • CNS Disorders • Migraine • Pain • Women's Health
http://www.ncbi.nlm.nih.gov/pubmed/42808257
 
Jelena Pejic; Jessica Ailani; Jeya Anandakumar; Lisa A Marks; Rashmi B Halker Singh
 
Sep 30, 2026
 
Prev Next